Clinical-stage Healthcare Company Announces Results From Alzheimer's Treatment Trial

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing treatments for neurodegenerative disorders, has announced promising results from their proof-of-concept Phase 2 SHINE trial. This study evaluated the efficacy of CT1812, an oral medication, in patients with mild-to-moderate Alzheimer's disease. The results indicate consistent cognitive improvement among participants treated with CT1812, compared to those on a placebo. This article delves into the details of the trial, the importance of the findings, and the future implications for Alzheimer's treatment. $Cognition Therapeutics(CGTX.US)$